e-learning
resources
Glasgow 2004
Sunday 05.09.2004
New aspects of drug therapy in paediatric asthma
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Montelukast reduces viral-induced asthma exacerbations: the PREVIA study
H. Bisgaard, M. L. Garcia Garcia, L. Gilles, J. Menten, C. Tozzi, P. Polos (Copenhagen, Denmark; Madrid, Spain; Whitehouse Station, United States Of America)
Source:
Annual Congress 2004 - New aspects of drug therapy in paediatric asthma
Session:
New aspects of drug therapy in paediatric asthma
Session type:
Oral Presentation
Number:
1348
Disease area:
Airway diseases, Paediatric lung diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
H. Bisgaard, M. L. Garcia Garcia, L. Gilles, J. Menten, C. Tozzi, P. Polos (Copenhagen, Denmark; Madrid, Spain; Whitehouse Station, United States Of America). Montelukast reduces viral-induced asthma exacerbations: the PREVIA study. Eur Respir J 2004; 24: Suppl. 48, 1348
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Management of Severe Asthma in Pediatric Patients by an Interdisciplinary Team in a Public Hospital Setting.
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Related content which might interest you:
Could montelukast reduce asthma exacerbations?
Source: Annual Congress 2008 - Advances in the treatment and pathogenesis of pulmonary diseases
Year: 2008
Montelukast and frequency of exacerbations of asthma
Source: Eur Respir J 2005; 26: Suppl. 49, 254s
Year: 2005
Increase in α-defensins during rhinovirus-induced experimental asthma exacerbations
Source: Eur Respir J 2006; 28: Suppl. 50, 154s
Year: 2006
Tiotropium reduces COPD exacerbations: the MISTRAL study
Source: Eur Respir J 2004; 24: Suppl. 48, 513s
Year: 2004
Asthma control and exacerbation rate with omalizumab in Italian patients with severe allergic asthma: PROXIMA study
Source: International Congress 2017 – Asthma management
Year: 2017
Characterising asthma exacerbations in the CAPTAIN trial
Source: Virtual Congress 2020 – Asthma and cough: clinical trials and pharmacological insights
Year: 2020
Montelukast in cases of severe asthma
Source: Eur Respir J 2002; 20: Suppl. 38, 407s
Year: 2002
Omalizumab treatment reduces asthma exacerbations in children with moderate or severe persistent asthma
Source: International Congress 2017 – Paediatric asthma: treatment modalities and behavioural issues
Year: 2017
Comparison of fluticasone, roflumilast and tiotropium in a model of influenza-induced acute COPD exacerbation
Source: Annual Congress 2013 –New drugs in respiratory medicine
Year: 2013
Roflumilast but not dexamethasone or fluticasone reduces neutrophilic airway inflammation and hyperreactivity in a murine influenza-induced asthma exacerbation model
Source: International Congress 2016 – Novel mechanisms and treatment modalities in asthma
Year: 2016
Once-daily glycopyrronium improves lung function and reduces exacerbations in severe-to-very severe COPD patients: The SPARK study
Source: Annual Congress 2013 –New bronchodilators for COPD management
Year: 2013
Omalizumab therapy reduces asthma exacerbations in children with severe allergic (IgE-mediated) asthma irrespective of lung function at baseline
Source: Annual Congress 2009 - Difficult asthma in children: diagnostic and therapeutic challenges
Year: 2009
Omalizumab reduces asthma exacerbations in children (6–<12 years) with moderate-to-severe allergic (IgE-mediated) asthma irrespective of baseline LABA use
Source: Annual Congress 2009 - Drug treatment of childhood asthma: the controversies and the issues
Year: 2009
Bacterial lysates in the prevention of asthma exacerbations in uncontrolled asthma: the Breathe study
Source: International Congress 2018 – Understanding the immunopathology that underlies airway obstructive diseases
Year: 2018
Montelukast and the prevention of viral induced asthma (The PREVIA Study)
Source: Eur Respir J 2003; 22: Suppl. 45, 533s
Year: 2003
Late Breaking Abstract: Inhaled pitrakinra, an IL-4/IL-13 antagonist, reduced exacerbations in patients with eosinophilic asthma
Source: Annual Congress 2010 - Treatment options for asthma
Year: 2010
Dexamethasone or prednisolone for acute asthma exacerbations in children: a meta-analysis
Source: International Congress 2019 – Severe acute asthma and troublesome wheezing
Year: 2019
Montelukast as add-on therapy in severe noninfectious COPD exacerbations
Source: Eur Respir J 2003; 22: Suppl. 45, 241s
Year: 2003
Real-life effectiveness of omalizumab in patients with severe persistent allergic asthma: the PERSIST study
Source: Annual Congress 2009 - Towards improving asthma control
Year: 2009
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept